The performance status gap in immunotherapy for frail patients with advanced non-small cell lung cancer

The performance status gap in immunotherapy for frail patients with advanced non-small cell lung cancer

Abstract Purpose In advanced non-small cell lung cancer (NSCLC), immune checkpoint inhibitor (ICI) monotherapy is often preferred over intensive ICI treatment for frail patients and those with poor performance status (PS). Among those with poor PS, the additional effect of frailty on treatment selec...

Full description

Saved in:
Bibliographic Details
Main Authors: Julie Tsu-Yu Wu, June Corrigan, Chloe Su, Clark Dumontier, Jennifer La, Aparjita Khan, Shipra Arya, Alex H. S. Harris, Leah Backhus, Millie Das, Nhan V. Do, Mary T. Brophy, Summer S. Han, Michael Kelley, Nathanael R. Fillmore
Format: Article
Language:English
Published: Springer 2024-07-01
Series:Cancer Immunology, Immunotherapy
Subjects:
Frailty
Performance status
Lung cancer
Online Access:https://doi.org/10.1007/s00262-024-03763-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s00262-024-03763-w

Similar Items